AstraZeneca Lifts Profit Guidance on Cancer, Diabetes Drugs
- Drugmaker sees core EPS rising by low thirties percentage
- Astra reaps benefits of a decade-long R&D investment
This article is for subscribers only.
AstraZeneca Plc raised its profit guidance for this year, saying drugs like Farxiga for diabetes and Tagrisso for cancer are fueling demand.
Core earnings per share excluding some items could grow by a percentage in the low thirties, up from the high twenties, despite contrary currency effects, the UK drugmaker said in a statement Thursday. Profit and sales beat analysts’ estimates in the latest quarter.